AI & Diagnostics Software in New York

Kemtai is a FDA-listed, CE-marked, HIPAA- and GDPR-compliant digital physical therapy platform that delivers AI-guided exercise and assessment software for rehabilitation, physical therapy, and wellness programs. The company develops computer vision technology that analyzes 111 body data points to provide real-time corrective feedback during exercises without requiring sensors or wearables. Kemtai serves health systems, hospitals, rehabilitation centers, payers (insurers, HMOs, value-based care organizations), digital health platforms, and medical device manufacturers. The platform includes Kemtai CARE, a standalone clinician app for managing patients, assigning exercise protocols, ROM assessments, and tracking adherence and performance metrics. Core capabilities include a library of 2,000+ exercises and movement variations, automated patient notifications, in-app messaging, and white-label customization. Integration is available via robust API framework for embedding into third-party platforms. Clinical validation demonstrates 72% average patient adherence, 33% reduction in in-person appointments, and 95% patient satisfaction. The technology is designed for at-home guided rehab, pre-operative therapy, post-operative recovery tracking, and chronic condition management across MSK, cardiac, neurological, and obesity care. Processing occurs on-device with no video recording, ensuring maximum privacy compliance.

Morphle Labs Inc. is an AI-enabled health tech company specializing in digital pathology and cancer diagnostics automation. The company develops robotic whole slide scanners, robotic microtomes, and intelligent image management systems designed to enhance pathology lab workflows. Their product portfolio addresses tissue preparation, high-throughput slide scanning, AI-driven image analysis, and digital archiving. The MorphoLens scanner family (240, 6, 1 variants) and HemoLens platform serve anatomical pathology, dermatopathology, hematology, and cytology applications. Morphle's solutions enable telepathology, reduce turnaround time, improve diagnostic accuracy, and support research institutions and cancer hospitals globally. The company holds 25+ patents and emphasizes superior image quality, LIS integration, and compact data storage formats.

RaySearch Laboratories is a Swedish medical software company specializing in oncology treatment planning and management solutions. The company develops advanced software platforms that enable cancer treatment centers to optimize radiation therapy, chemotherapy, and adaptive care workflows. RaySearch's primary offering is RayCare, an integrated oncology information system designed to support thousands of clinics worldwide. The company collaborates with leading cancer centers to translate scientific advancements into clinical solutions. RaySearch operates in the radiation oncology and comprehensive cancer care software space, serving hospitals and specialized cancer treatment facilities globally. The company is publicly traded (AB publ) and maintains active participation in major oncology conferences including ECIO and IBA's International Symposium on Proton Therapy. Recent expansion includes market entry in China with initial RayCare orders.

Radformation is a healthcare technology company specializing in AI-driven automation software for radiation oncology workflows. Founded in 2016 and based in New York, the company develops intelligent tools that enhance efficiency, reduce errors, and improve cancer treatment planning across oncology clinics. Radformation's integrated platform supports the complete treatment lifecycle—from automated contouring and planning to quality assurance, treatment monitoring, and billing automation. Key offerings include AutoContour (480+ deep-learning anatomical structures), EZFluence (3D automated planning), ClearCheck (plan evaluation), ClearCalc (independent dose calculation), RadMonteCarlo (Monte Carlo calculations), ChartCheck (real-time treatment monitoring), ChartCheck Adaptive (adaptive dose tracking), QuickCode (billing QA), and RadMachine (machine QA). The platform seamlessly integrates with Eclipse™ TPS and supports photon, electron, proton, and brachytherapy modalities. With over 1,400 clinic installations and multiple regulatory clearances, Radformation enables cancer treatment centers to standardize workflows, increase patient throughput, and deliver safer, higher-quality radiation treatments.

Aptar Digital Health, a division of Aptar Pharma and part of AptarGroup, Inc., is a comprehensive digital health solutions provider headquartered in Congers, New York. The company specializes in developing and deploying regulated digital therapeutics, companion mobile applications, and connected drug-delivery systems tailored for pharmaceutical and biotechnology partners globally. Aptar Digital Health operates across 120 countries with 20+ years of digital health leadership, supporting 15+ regulatory approvals and 17+ clinical studies. The platform is ISO 13485 and ISO 27001 certified, MDSAP-compliant, and adheres to HIPAA and GDPR standards. Core offerings include Software as a Medical Device (SaMD), Digital Patient Support Programs (PSPs), Disease Management Platforms, and Real-World Evidence generation services. Therapeutic focus areas encompass oncology, respiratory care, neurology (migraine, multiple sclerosis), immunology, and chronic disease management. The company's integrated platform enables pharmaceutical partners to enhance treatment adherence, optimize patient engagement across the entire treatment journey, and generate actionable clinical insights through connected devices and user community analytics.

Chembio Diagnostics, Inc. is a leading developer and manufacturer of rapid point-of-care (POC) diagnostic tests for infectious diseases, headquartered in Hauppauge, New York, with operations in Medford, New York. The company specializes in innovative diagnostic solutions utilizing its proprietary Dual Path Platform (DPP®) technology, which delivers improved sensitivity, multiplexing capabilities, and rapid results from a small sample of fingertip blood. Chembio's product portfolio includes FDA-approved and CLIA-waived assays for HIV, syphilis, Hepatitis C, COVID-19, and emerging infectious disease detection. The company also develops quantitative diagnostics (FastPack® hCG) and is actively advancing diagnostics for typhoid fever and preeclampsia. With 337 employees and approximately $55.3 million in annual revenue, Chembio markets its solutions to medical laboratories, hospitals, government health agencies, NGOs, and retail establishments across the United States and internationally. The company is committed to delivering exceptional, easy-to-use, fast, and accurate diagnostic solutions to enhance health outcomes in infectious disease detection and monitoring.

The Jacobs Institute is a not-for-profit vascular medical technology innovation center located in Buffalo, New York, uniquely positioned as the only independently managed medical innovation facility operating within a single building. Strategic proximity to Kaleida Health's Gates Vascular Institute and the University at Buffalo's Clinical and Translational Research Center enables seamless collaboration for medical device development. The institute's core mission centers on accelerating next-generation vascular medicine technologies through partnerships between physicians, engineers, entrepreneurs, and industry stakeholders. Key service offerings include the i2R (Idea to Reality) Center, which guides medical device development from ideation through FDA submission; regulatory and quality compliance services; clinical training programs; and a 3D Printing Center of Excellence in Health Care specializing in customizable 3D-printed vascular flow models for anatomical visualization and product testing. The institute also operates education and community programs designed to inspire future healthcare professionals and advance vascular medicine innovation.